Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal fragment of endogenous human growth hormone-releasing hormone (GHRH 1-44), synthesised with a C-terminal amide and commonly referenced in the literature as GRF(1-29)-NH2. AminoOptimization Group supplies it as a lyophilised research powder in a 10 mg presentation, tested to 99% purity by HPLC, with a Certificate of Analysis available for the lot supplied. This material is offered strictly for laboratory research use. It is not a drug, and it is not for human or veterinary use.
What is Sermorelin?
Sermorelin reproduces the first 29 residues of native human GHRH without substitution — the identical sequence identified in early isolation studies as the shortest GHRH fragment that retains full receptor-binding activity relative to the intact 44-residue hormone. The C-terminal amide is functionally significant: amidation at this position is described in the receptor-binding literature as necessary for high-affinity engagement of the GHRH receptor (GHRHR), and its absence substantially reduces activity in binding assays.
Because the sequence is unmodified, Sermorelin remains a substrate for the same peptidases that degrade endogenous GHRH, including dipeptidyl peptidase-4 (DPP-4) cleavage at the N-terminus. This is the property that most distinguishes it, in study design terms, from engineered long-acting GHRH analogues such as CJC-1295, which introduce amino acid substitutions specifically to resist that degradation. Sermorelin’s comparatively rapid clearance is a variable researchers control for directly, rather than a limitation to be engineered around, in work examining native-sequence receptor pharmacology.
This makes Sermorelin a reference point in structure-activity work: it represents the unmodified ligand against which stabilised or extended-half-life analogues are compared for relative potency, receptor occupancy, and degradation kinetics.
Specifications
- Compound: Sermorelin (GRF 1-29)
- CAS number: 86168-78-7
- Molecular formula: C149H246N44O42S
- Molecular weight: 3357.9 g/mol
- Purity: 99% HPLC
- Presentation: Lyophilised powder, sealed vial
- Available sizes: 10 mg
- Physical form: White to off-white powder
- Classification: Research peptide — not for human or veterinary use
Research context
As the native GHRH(1-29) sequence, Sermorelin is studied primarily for what it reveals about GHRH receptor pharmacology at the anterior pituitary. Published work examines receptor-binding kinetics, downstream cAMP-mediated signalling in somatotroph cell models, and how closely the truncated fragment’s activity tracks that of full-length GHRH(1-44) across assay conditions.
Its short circulating half-life makes it a frequent reference ligand in comparative pharmacokinetic work: study designs benchmarking engineered analogues for extended activity typically include native-sequence Sermorelin as the unmodified control. It also appears in models investigating the pulsatile nature of GH secretion, where the signal’s rapid rise and clearance — rather than sustained receptor occupancy — is the variable under examination.
None of this literature establishes safety or efficacy for use in humans. It is provided as research context only.
Reconstitution
Lyophilised peptide requires reconstitution with a suitable sterile diluent before use in solution. Bacteriostatic water is the diluent most commonly specified for multi-use laboratory preparations; sterile water is typical for single-use work.
Direct the diluent stream against the inner wall of the vial rather than onto the powder itself, and allow the material to dissolve without agitation. Peptides are susceptible to shear stress — do not shake the vial. Swirl gently if needed, and expect full dissolution within a few minutes at room temperature.
Working concentration is a function of how much diluent you add to a given vial mass. Our peptide reconstitution calculator computes the resulting concentration for any combination of vial size and diluent volume.
Storage and stability
Before reconstitution: store the sealed vial in a freezer at -20 °C, protected from light. Lyophilised peptide is comparatively stable in this state. Brief excursions to ambient temperature during shipping are normal and are not expected to compromise a properly lyophilised product.
After reconstitution: refrigerate at 2–8 °C and protect from light. Reconstituted peptide in solution is materially less stable than the dry powder, and Sermorelin’s short half-life in biological systems has no bearing on its shelf stability in solution under refrigeration. Avoid repeated freeze-thaw cycles, which are a well-documented cause of aggregation and loss of measurable potency — aliquot instead if repeated sampling is required.
Inspect solutions before use. Cloudiness, visible particulate, or discolouration indicate the material should not be relied upon for quantitative work.
Certificate of Analysis
Every lot is tested by high-performance liquid chromatography, and the purity figure shown above refers to analytical results for the specific lot supplied — not to a generic specification. A Certificate of Analysis is available on request, and we will provide lot-specific documentation before purchase if your protocol requires it.
Purity by HPLC describes the proportion of the target peptide relative to detectable related substances. It is a statement about the material as manufactured and tested. It is expressly not a representation that the material is suitable for any use in humans or animals.
Handling and safety
Handle in accordance with good laboratory practice. Use appropriate personal protective equipment, work in a suitable containment environment, and dispose of material and consumables according to your institution’s requirements and applicable local regulation. Anyone with access to this material should understand that it is not for human or veterinary use.
Frequently asked questions
What is the difference between Sermorelin and CJC-1295?
Sermorelin is the unmodified native GHRH(1-29) sequence, while CJC-1295 introduces amino acid substitutions designed to resist enzymatic degradation and extend circulating half-life. Researchers select between them depending on whether a study design calls for native-sequence pharmacology or a longer-acting analogue.
Is Sermorelin approved in Canada?
No. This compound has not been evaluated or authorised by Health Canada, the FDA, or any comparable regulatory authority. It carries no DIN or NPN, its safety and efficacy for human use have not been assessed, and it is supplied for laboratory research only.
How much diluent should be used?
That depends on the working concentration your protocol requires. Use the reconstitution calculator to work out the resulting concentration for your vial size.
How long is reconstituted material usable?
Stability in solution is shorter than in lyophilised form and depends on diluent, temperature, and handling. Refrigerate at 2–8 °C, protect from light, avoid freeze-thaw cycling, and validate stability for your own storage conditions if your work depends on it.
Do you provide a Certificate of Analysis?
Yes — lot-specific, available on request, including before purchase.
Research use only
This product is supplied solely for laboratory and scientific research. It is not a drug, food, cosmetic, or medical device, and it must not be administered to humans or animals. Nothing on this page is medical advice or a therapeutic claim. Full terms are set out in our Research Use Only Disclaimer.
Reviews
There are no reviews yet.